LG Chem said Thursday it signed an exclusive distribution agreement with Japan's Mochida Pharmaceutical to sell endometriosis treatment Dinagest in South Korea and Thailand. The deal is aimed at strengthening the company's women's health portfolio.
Dinagest is an oral progestogen containing dienogest, widely used as a key treatment for hormone-dependent women's conditions such as endometriosis. It is the only product in Japan's dienogest market that has conducted clinical trials and demonstrated therapeutic efficacy across endometriosis, adenomyosis, and dysmenorrhea (menstrual pain). Dinagest currently holds more than 80% market share in Japan, ranking first in the market, according to LG Chem.
Through its partnership with Mochida Pharmaceutical, LG Chem plans to apply for domestic marketing approval for Dinagest next year. The company also aims to expand its women's health solution lineup, including medications for embryo implantation maintenance and miscarriage prevention, to improve treatment accessibility for women's conditions. LG Chem currently supplies products spanning the entire in vitro fertilization (IVF) process, from ovulation inducers such as Folytrop and Ganirever to egg and embryo cryo-preservation and thawing products. Since last year, the company has also offered Bloom, a mobile application that assists with pregnancy preparation and infertility treatment.
"The introduction of Dinagest marks an important starting point in expanding our existing infertility business into a broader women's health business," said Kim Sung-ho, head of LG Chem's Specialty Care business unit. "We will continue to discover and develop products that provide practical support for women's health management across every stage of life."